Clinical Trials for Trametinib

1 Open Trial

Trial TypeProtocol No. &
Open Date
Summary
TreatmentVICCMELP1388
03/24/2014
A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, trametinib, Combined with the CDK4/6 Inhibitor, palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects with Solid Tumors.

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.